Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 21, 2026, 5:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 441 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Urothelial Carcinoma Bladder Clear all
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Non-Muscle Invasive Bladder Cancer ("NMIBC") Unresponsive/Intolerant to BCG
Interventions
Ruvidar® (TLD-1433) bladder infusion and PDT
Combination Product
Lead sponsor
Theralase® Technologies Inc.
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2027
U.S. locations
10
States / cities
Chicago, Illinois • Greenwood, Indiana • Syracuse, New York + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Urinary Bladder Neoplasm
Interventions
Mitomycin C
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Dec 2, 2015 · Synced May 21, 2026, 5:35 PM EDT
Recruiting No phase listed Observational
View directory record Official record
Conditions
Bladder Cancer, Metastatic Bladder Cancer, Unresectable Bladder Carcinoma, Urothelial Carcinoma
Interventions
Geriatric-8 Survey, National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18), Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
65 Years and older
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 16, 2026 · Synced May 21, 2026, 5:35 PM EDT
Completed Early Phase 1 Interventional
View directory record Official record
Conditions
Bladder Urothelial Carcinoma, Urothelial Carcinoma
Interventions
Copper Cu 64 TP3805, Positron Emission Tomography, Computed Tomography
Drug · Procedure
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 21, 2025 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Breast Cancer, Gastric Cancer, Renal Cell Carcinoma, Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Cholangiocarcinoma, Bladder Urothelial Carcinoma, MSI-H Colorectal Cancer, Esophageal Cancer, Hepatic Cancer, Head and Neck Cancer, Other Solid Tumors
Interventions
CDX-527
Drug
Lead sponsor
Celldex Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Atlanta, Georgia • Chicago, Illinois • Omaha, Nebraska + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2023 · Synced May 21, 2026, 5:35 PM EDT
Recruiting Phase 1Phase 2 Interventional
View directory record Official record
Conditions
Bladder Cancer
Interventions
MK-3120, EV, Pembrolizumab, Rescue Medication
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
3
States / cities
San Francisco, California • Cleveland, Ohio • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced May 21, 2026, 5:35 PM EDT
Terminated Not applicable Interventional
View directory record Official record
Conditions
Stage 0is Bladder Urothelial Carcinoma, Stage I Bladder Urothelial Carcinoma, Stage II Bladder Urothelial Carcinoma, Stage III Bladder Urothelial Carcinoma
Interventions
Questionnaire Administration, Radical Cystectomy
Other · Procedure
Lead sponsor
University of Southern California
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 2, 2019 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Urothelial/Bladder Cancer, Nos
Interventions
Atezolizumab, PGV001, Poly ICLC, Normal saline
Drug · Biological
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 15, 2023 · Synced May 21, 2026, 5:35 PM EDT
Withdrawn Not applicable Interventional
View directory record Official record
Conditions
Infiltrating Bladder Urothelial Carcinoma
Interventions
Quality-of-Life Assessment, Questionnaire Administration
Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2020 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Urothelial Carcinoma, Urothelial Carcinoma Bladder, Bladder Cancer, Bladder Disease, Solid Tumor, Solid Carcinoma, Solid Tumor, Adult, Metastatic Cancer, Advanced Solid Tumor, Advanced Cancer, Metastatic Bladder Cancer, Metastatic Urothelial Carcinoma, Locally Advanced Solid Tumor, Neoplasms, Neoplasm Metastasis, Neoplasm Malignant, Neoplasm, Bladder, Urothelial Neoplasm, Neoplasm, Urinary Bladder, Bladder Neoplasm, Bladder Urothelial Carcinoma
Interventions
IK-175, IK-175 and nivolumab
Drug
Lead sponsor
Ikena Oncology
Industry
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
10
States / cities
Gilbert, Arizona • Sarasota, Florida • Chicago, Illinois + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 14, 2024 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
MV-NIS
Biological
Lead sponsor
Vyriad, Inc.
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
3
States / cities
Miami, Florida • New Orleans, Louisiana • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 26, 2023 · Synced May 21, 2026, 5:35 PM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
gemcitabine hydrochloride, paclitaxel
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
Up to 120 Years
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2011
U.S. locations
92
States / cities
Mobile, Alabama • Little Rock, Arkansas • Los Angeles, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2016 · Synced May 21, 2026, 5:35 PM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Locally Advanced Bladder Urothelial Carcinoma, Locally Advanced Renal Pelvis Urothelial Carcinoma, Locally Advanced Ureter Urothelial Carcinoma, Locally Advanced Urethral Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma, Metastatic Bladder Urothelial Carcinoma, Metastatic Renal Pelvis Urothelial Carcinoma, Metastatic Ureter Urothelial Carcinoma, Metastatic Urethral Urothelial Carcinoma, Metastatic Urothelial Carcinoma
Interventions
Pembrolizumab, Nivolumab, Atezolizumab, Durvalumab, Avelumab
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
377
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Phoenix, Arizona + 260 more
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer
Interventions
cisplatin, 5-fluorouracil, Mitomycin, Three-Dimensional Conformal Radiation Therapy
Drug · Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
18 Years to 120 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2023
U.S. locations
13
States / cities
Atlanta, Georgia • Baltimore, Maryland • Fall River, Massachusetts + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced May 21, 2026, 5:35 PM EDT
Active, not recruiting Phase 2 Interventional
View directory record Official record
Conditions
Urothelial Carcinoma, Bladder Cancer
Interventions
Abiraterone acetate, Durvalumab, Methotrexate, Vinblastine, Doxorubicin Hydrochloride, Cisplatin
Other · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
2
States / cities
Bloomington, Indiana • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2026 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Urothelial Carcinoma of the Bladder
Interventions
Proton therapy, IMRT
Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 25, 2019 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 1 Interventional Results available
View directory record Official record
Conditions
Metastatic Cancer, Solid Tumors, Colorectal Cancer (CRC), Gastric Cancer, Head and Neck Cancer, Lung Cancer, Renal Cell Carcinoma (RCC), Bladder Cancer, UC (Urothelial Cancer), Mesothelioma
Interventions
INCB001158, Pembrolizumab
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
13
States / cities
Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2025 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Urinary Bladder Neoplasms
Interventions
larotaxel (XRP9881), gemcitabine, cisplatin
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
337 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
52
States / cities
Anchorage, Alaska • Berkeley, California • Burbank, California + 46 more
Source: ClinicalTrials.gov public record
Updated May 4, 2016 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Carcinoma of Urinary Tract, Urethral Carcinoma, Carcinoma of Ureter, Carcinoma of Renal Pelvis
Interventions
Docetaxel, Ramucirumab DP, Icrucumab
Drug · Biological
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
148 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
26
States / cities
Los Angeles, California • Sacramento, California • San Francisco, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 8, 2019 · Synced May 21, 2026, 5:35 PM EDT
Active, not recruiting Phase 3 Interventional Results available
View directory record Official record
Conditions
Various Advanced Cancer
Interventions
Nivolumab, Placebo
Biological · Other
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
709 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2027
U.S. locations
33
States / cities
Anchorage, Alaska • Tucson, Arizona • Clovis, California + 27 more
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 3 Interventional Results available
View directory record Official record
Conditions
Urothelial Carcinoma
Interventions
Atezolizumab, Carboplatin, Gemcitabine, Placebo, Cisplatin
Drug · Other
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
1,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2024
U.S. locations
18
States / cities
Rogers, Arkansas • San Luis Obispo, California • New Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 23, 2025 · Synced May 21, 2026, 5:35 PM EDT
Withdrawn Phase 2 Interventional
View directory record Official record
Conditions
Bladder Cancer
Interventions
Durvalumab, Tremelimumab, Radiation Therapy
Drug · Radiation
Lead sponsor
Terence Friedlander, MD
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2017 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Carcinoma, Transitional Cell, Bladder Cancer, Bladder Neoplasm
Interventions
Pralatrexate Injection, Vitamin B12, Folic Acid
Drug · Dietary Supplement
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
4
States / cities
Tucson, Arizona • Atlanta, Georgia • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2019 · Synced May 21, 2026, 5:35 PM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter, Urethral Cancer
Interventions
carboplatin, gemcitabine, paclitaxel, surgery
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2011
U.S. locations
128
States / cities
Anchorage, Alaska • Glendale, Arizona • Mesa, Arizona + 89 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced May 21, 2026, 5:35 PM EDT